@RNAiAnalyst Nothing wrong with data, but $ABUS either needs to raise cash or sell / partner their siRNA asset. And they don't have much negotiating leverage. Requires $GILD or $ASMB to step up &amp; decide to enter a crowded race in 4th place (behind $ARWR / $JNJ, $DRNA / Roche, $ALNY / $VIR).